Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 36th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
CDNA	CAREDX INC	$3.31B	51,734,223	0.10%	29.95%	Net Selling	Net Selling
SHC	SOTERA HEALTH CO	$5.31B	285,374,795	0.10%	4.47%	Net Selling	Net Selling
NEOG	NEOGEN CORP	$2.78B	218,056,016	0.11%	1.94%	Net Buying	Net Buying
DGX	QUEST DIAGNOSTICS INC	$25.60B	110,373,360	0.10%	1.81%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$25.04B	81,100,000	0.10%	1.63%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	$2.41B	128,475,440	0.11%	37.94%	Net Selling	Net Selling
TMO	THERMO FISHER SCIENTIFIC INC	$251.28B	369,747,286	0.09%	0.93%	Net Buying	Net Selling
CSTL	CASTLE BIOSCIENCES INC	$1.07B	30,549,507	0.09%	15.25%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	$44.28B	164,600,000	0.10%	84.74%	Net Selling	Net Selling
DHR	DANAHER CORP	$158.95B	702,986,054	0.08%	26.19%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$49.35B	281,928,854	0.09%	1.29%	Net Buying	Net Buying
WAT	WATERS CORP	$43.55B	98,248,111	0.10%	4.95%	Net Selling	Net Buying
ILMN	ILLUMINA INC	$41.07B	151,000,000	0.10%	9.10%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$30.80B	20,036,559	0.10%	5.13%	Net Buying	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$14.13B	47,738,872	0.12%	4.28%	Net Selling	Net Selling
RVTY	REVVITY INC	$17.05B	111,586,401	0.10%	3.00%	Net Selling	Net Selling
BDSX	BIODESIX INC	$307.46M	10,551,118	0.01%	99.99%	Net Buying	Net Buying
IDXX	IDEXX LABORATORIES INC	$42.02B	78,781,116	0.09%	1.82%	Net Selling	Net Buying
BLLN	BILLIONTOONE INC	$5.58B	47,187,038	0.03%	18.81%	Net Selling	Net Selling
RDNT	RADNET INC	$5.56B	78,697,257	0.10%	39.43%	Net Buying
XGN	EXAGEN INC	$201.07M	24,225,339	0.03%	46.67%	Net Selling	Net Selling
OPK	OPKO HEALTH INC	$1.21B	746,328,225	0.03%	99.97%	Net Buying	Net Selling
NTRA	NATERA INC	$59.75B	144,144,170	0.10%	21.99%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$17.36B	27,911,655	0.04%	99.96%	Net Selling	Net Selling
PRPO	PRECIPIO INC	$42.21M	1,790,188	0.00%	100.00%	Net Buying	Net Buying
STIM	NEURONETICS INC	$179.83M	76,197,222	0.05%	46.40%	Net Buying	Net Buying
QGEN	QIAGEN NV	$9.18B	206,801,000	0.07%	0.00%
TWST	TWIST BIOSCIENCE CORP	$11.67B	62,707,424	0.12%	14.65%	Net Selling	Net Selling
ICLR	ICON PLC	$13.14B	77,154,209	0.10%	0.54%	Net Selling	Net Selling
QUCY	QUANTUM CYBER NV	$108.45M	84,068,192	0.00%	68.12%	Net Buying	Net Buying
ADVB	ADVANCED BIOMED INC	$8.74M	1,382,133	0.00%	0.00%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$23.85B	134,196,170	0.10%	43.83%	Net Selling	Net Selling
GRAL	GRAIL INC	$6.10B	44,666,234	0.09%	18.53%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$777.21M	147,198,893	0.08%	53.53%	Net Selling	Net Selling
BIAF	BIOAFFINITY TECHNOLOGIES INC	$3.72M	540,115	0.02%	99.98%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$110.61M	32,724,284	0.02%	99.98%	Net Buying	Net Selling
FRNM	FREENOME INC	$1.70B	107,021,669	0.01%	24.56%	Net Buying	Net Buying
MYGN	MYRIAD GENETICS INC	$404.60M	95,649,645	0.09%	11.78%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$607.54M	27,515,293	0.06%	49.26%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$205.70M	108,604,241	0.00%	18.08%	Net Buying
MBAI	MBODY AI LTD	$3.76M	1,002,929	0.00%	100.00%
VNRX	VOLITIONRX LTD	$3.49M	13,649,384	0.00%	100.00%	Net Buying
ISPC	ISPECIMEN INC	$3.10M	2,518,590	0.00%	100.00%
XWEL	XWELL INC	$7.39M	8,589,266	0.00%	100.00%
DRIO	DARIOHEALTH CORP	$64.87M	9,799,481	0.01%	99.99%	Net Buying	Net Buying
MDXH	MDXHEALTH SA	$2.67M	51,364,520	0.03%	83.20%	Net Buying	Net Buying
PSNL	PERSONALIS INC	$1.75B	106,799,872	0.08%	34.31%	Net Buying	Net Selling
NDRA	ENDRA LIFE SCIENCES INC	$8.82M	1,499,838	0.01%	85.02%	Net Buying
TRIB	TRINITY BIOTECH PLC	$4.18M	12,473,555	0.01%	3.98%
SERA	SERA PROGNOSTICS INC	$79.29M	39,449,466	0.04%	25.79%	Net Selling	Net Selling

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 53, which is 24 points higher than the diagnostic & research industry average of 29.

CDNA passed 18 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 330.82% over the past year, overperforming other diagnostic & research stocks by 294 percentage points.

Caredx has an average 1 year price target of $61.67, a downside of -3.68% from Caredx's current stock price of $64.02.

Caredx stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Caredx, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 40, which is 11 points higher than the diagnostic & research industry average of 29.

SHC passed 14 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 18.1% over the past year, underperforming other diagnostic & research stocks by -19 percentage points.

Sotera Health Co has an average 1 year price target of $22.00, an upside of 18.28% from Sotera Health Co's current stock price of $18.60.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 80% have issued a Strong Buy rating, 0% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Neogen (NASDAQ:NEOG)

Neogen (NASDAQ:NEOG) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Neogen (NASDAQ:NEOG) is: Value: C, Growth: B, Momentum: A, Sentiment: B, Safety: C, Financials: C, and AI: C.

Neogen (NASDAQ:NEOG) has a Due Diligence Score of 16, which is -13 points lower than the diagnostic & research industry average of 29. Although this number is below the industry average, our proven quant model rates NEOG as a "A".

NEOG passed 5 out of 33 due diligence checks and has weak fundamentals. Neogen has seen its stock return 127.73% over the past year, overperforming other diagnostic & research stocks by 91 percentage points.

Neogen has an average 1 year price target of $14.00, an upside of 9.98% from Neogen's current stock price of $12.73.

Neogen stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Neogen, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 5.16%, which is 4 percentage points higher than the diagnostic & research industry average of 1.27%.

Qiagen Nv's dividend payout ratio of 243.6% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.27%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 34.8% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.93%, which is the same as the diagnostic & research industry average of 1.27%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.7% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.07% in the last day, and up 2.99% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 17 points higher than the diagnostic & research industry average of 12. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 1.05% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 31 points higher than the diagnostic & research industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has gained 4.23% in the past year. It has underperformed other stocks in the diagnostic & research industry by -33 percentage points.

3. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Sotera Health Co has a valuation score of 14, which is 2 points higher than the diagnostic & research industry average of 12. It passed 1 out of 7 valuation due diligence checks.

Sotera Health Co's stock has gained 18.1% in the past year. It has underperformed other stocks in the diagnostic & research industry by -19 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to fall by -2.71% over the next year.

7.69% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 15.38% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 10.26% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 9.82x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Caredx (NASDAQ:CDNA)

2. Sotera Health Co (NASDAQ:SHC)

3. Neogen (NASDAQ:NEOG)

1. Qiagen Nv (NYSE:QGEN)

2. Quest Diagnostics (NYSE:DGX)

3. Labcorp Holdings (NYSE:LH)

1. Qiagen Nv (NYSE:QGEN)

2. Icon (NASDAQ:ICLR)

3. Sotera Health Co (NASDAQ:SHC)

Company

Stock Tools

Stock Ideas